Congress removes cost barriers to lung cancer screening for millions
S. 4566 — Increasing Access to Lung Cancer Screening Act · Filed by Richard Durbin (D-IL) · 1 cosponsor · Introduced May 19, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill expands Medicaid and Medicare coverage of annual lung cancer screening and tobacco cessation counseling with no cost-sharing (copays, deductibles) for eligible individuals, removes prior authorization requirements across all insurance types, and funds a $10 million/year public education campaign (2028–2032). It also mandates a federal study to identify underscreened populations like firefighters, veterans, and younger women.
Why we flagged it
The bill's core function is to remove financial and administrative barriers to lung cancer screening and tobacco cessation across all major insurance types (Medicaid, Medicare, private). It is a preventive-health mandate, not a tax provision, subsidy, or commemorative measure.
What the text implies
- Removal of prior authorization for lung cancer screening may increase screening volume and associated imaging costs (CT scans), potentially straining radiology capacity in underserved areas.
- Expansion of tobacco cessation coverage to all Medicaid individuals (not just pregnant women) may increase pharmaceutical demand for nicotine-replacement and prescription cessation drugs, benefiting manufacturers.
The full analysis lists 5 implications of this text.
Who stands to gain
pharmaceutical companies (nicotine-replacement, cessation drugs); diagnostic imaging providers (CT scan volume increase); healthcare systems and hospitals (increased screening referrals)